Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Receivables (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Change in Receivables for 9 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 187.23% year-over-year to $20.1 million, compared with a TTM value of $21.3 million through Dec 2025, up 230.2%, and an annual FY2025 reading of $21.3 million, up 230.2% over the prior year.
  • Change in Receivables was $20.1 million for Q4 2025 at Puma Biotechnology, up from $7.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $26.5 million in Q3 2024 and bottomed at -$23.1 million in Q1 2024.
  • Average Change in Receivables over 5 years is $1.4 million, with a median of $627500.0 recorded in 2021.
  • The sharpest move saw Change in Receivables skyrocketed 1569.19% in 2021, then tumbled 992.2% in 2022.
  • Year by year, Change in Receivables stood at $8.7 million in 2021, then skyrocketed by 41.17% to $12.3 million in 2022, then surged by 56.09% to $19.2 million in 2023, then plummeted by 219.76% to -$23.0 million in 2024, then skyrocketed by 187.23% to $20.1 million in 2025.
  • Business Quant data shows Change in Receivables for PBYI at $20.1 million in Q4 2025, $7.4 million in Q3 2025, and $376000.0 in Q2 2025.